BioSpace News Archive

Immuneering Corporation today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors.

NeuroGenesis Bio Inc. announced positive results from the interim analysis of the open-label extension period of a randomized, double-blind, placebo-controlled, Phase 2 clinical trial assessing the long-term effects of its lead asset, NG-01, on the two main serum biomarkers of MS activity and progression, on physical and cognitive assessments, and patient-reported outcomes in progressive MS.

Azenta, Inc. announced that Company management will participate in Virtual KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, which includes a presentation beginning at 12:45 pm ET.

Alcanza Clinical Research, a mission-focused investigator site network, has appointed James Clark, M.D., as its first-ever Chief Medical Officer, marking a milestone in Alcanza’s growth journey as it expands its network size and patient reach.

Basecamp Research announced the launch of BaseFold, its new deep learning model that predicts 3D structures of large, complex proteins more accurately than other AI-powered tools, including the industry gold standard, AlphaFold2.

Hyphens Pharma International Limited is pleased to announce that its subsidiary, Hyphens Pharma Pte. Ltd., has entered into an exclusive license, supply and commercialisation agreement with MC2 Therapeutics for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.

Regulus Therapeutics Inc. announced positive topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.

KalVista Pharmaceuticals, Inc. announced the UK Medicines and Healthcare products Regulatory Agency has awarded the Promising Innovative Medicine designation for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema.

High-dose glucocorticoid regimes do not improve outcomes compared to standard dose but carry greater risk of side effects Glucocorticoid treatment does not result in complete recovery in 60% of patients New treatment options for sudden hearing loss patients are urgently needed High-dose glucocorticoids are no more effective than the standard-dose in treating patients with sudden hearing loss.

Element Biosciences, Inc., developer of pioneering technologies to empower science, announced the appointment of Danae Van Oene as Senior Vice President of Global Sales and Support.